Importance of CD8 T cell-mediated immune response during intracellular parasitic infections and its implications for the development of effective vaccines

Anais da Academia Brasileira de Ciencias

Volumn 75, Issue 4, 2003, Pages 443-468

  Rodrigues, Mauricio M ^a   Boscardin, Silvia B ^a   Vasconcelos, José R ^a   Hiyane, Meire I ^a   Salay, Gerson ^a   Soares, Irene S ^b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

CD8; Immunity; Parasites; Vaccine

Indexed keywords

ANIMALIA; TOXOPLASMA GONDII; TRYPANOSOMA; TRYPANOSOMA CRUZI;

EID: 0345016871     PISSN: 00013765     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0001-37652003000400005     Document Type: Article

References (97)

1. AIDOO M, LALVANI A, ALLSOPP CE, PLEBANSKI M, MEISNER SJ, KRAUSA P, BROWNING M, MORRIS-JONES S, GOTCH F, FIDOCK DA AND AL E. 1995. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria. Lancet 345: 1003-1007.
2. ALIBERTI JC, MACHADO FS, SOUTO JT, CAMPANELLI AP, TEIXEIRA MM, GAZZINELLI RT AND SILVA JS. 1999. beta-Chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun 67: 4819-4826.
3. ALLEN TM, VOGEL TU, FULLER DH, MOTHE BR, STEFFEN S, BOYSON JE, SHIPLEY T, FULLER J, HANKE T, SEITE A, ALTMAN JD, MOSS B, MCMICHAEL AJ AND WATKINS DI. 2000. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164: 4968-4978.
4. ANGUS CW, KLIVINGTON-EVANS D, DUBEY JP AND KOVACS JA. 2000. Immunization with a DNA plasmid encoding the SAG1 (P30) protein of Toxoplasma gondii is immunogenic and protective in rodents. J Infect Dis 181: 317-324.
5. BELKAID Y, VON STEBUT E, MENDEZ S, LIRA R, CALER E, BERTHOLET S, UDEY MC AND SACKS D. 2002. CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol 168: 3992-4000.
6. BONELO A, VALMORI D, TRIPONEZ F, TTERCY JM, MENTHA G, OBERHOLZER J, CHAMPAGNE P, ROMERO JF, ESPOSITO F, NEBIE I, BARBEY C, ROMERO P, HERRERA S, CORRADIN G AND LOPEZ JA. 2000. Generation and characterization of malaria-specific human CD8(+) lymphocyte clones: effect of natural polymorphism on T cell recognition and endogenous cognate antigen presentationby liver cells. Eur J Immunol 30: 3079-3088.
7. BOTTREL RL, DUTRA WO, MARTINS FA, GONTIJO B, CARVALHO E, BARRAL-NETTO M, BARRAL A, ALMEIDA RP, MAYRINK W, LOCKSLEY R AND GOLLOB KJ. 2001. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble Leishmania antigen in human cutaneous Leishmaniasis. Infect Immun 69: 3232-3239.
8. BRODSKYN CI, BARRAL A, BOAVENTURA V, CARVALHO E AND BARRAL-NETTO M. 1997. Parasite-driven in vitro human lymphocyte cytotoxicity against autologous infected macrophages from mucosal Leishmaniasis. J Immunol 159: 4467-4473.
9. BRUNA-ROMERO O, GONZALEZ-ASEGUINOLAZA G, HAFALLA JC, TSUJI M AND NUSSENZWEIG RS. 2001. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc Natl Acad Sci USA 98: 11491-11496.
10. CARVALHO LH, SANO G, HAFALLA JC, MORROT A, CUROTTO DE LAFAILLE MA, ZAVALA F. 2002. IL-4-secreting CD4+ T cells are crucial to the development of CD8+ T-cell responses against malaria liver stages. Nat Med 8: 166-170.
11. COSTA F, FRANCHIN G, PEREIRA-CHIOCCOLA VL, RlBEIRAO M, SCHENKMAN S AND RODRIGUES MM. 1998. Immunization with a plasmid DNA containing the gene of trans-sialidase reduces Trypanosoma cruzi infection in mice. Vaccine 16: 768-774.
12. DE LUCA PM, MAYRINK W, LVES CR, COUTINHO SG, OLIVEIRA MP, BERTHO AL, TOLEDO VP, COSTA CA, GENARO O AND MENDONCA SC. 1999. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary Leishmaniasis. Vaccine 17: 1179-1185.
13. DENKERS EY AND GAZZINELLI RT. 1998. Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection. Clin Microbiol Rev 11: 569-588.
14. DENKERS EY, YAP G, SCHARTON-KERSTEN T, CHAREST H, BUTCHER BA, CASPAR P, HEINY S AND SHER A. 1997. Perforin-mediated cytolysis plays a limited role in host resistance to Toxoplasma gondii. J Immunol 159: 1903-1908.
15. DESOLME B, MEVELEC MN, BUZONI-GATEL D AND BOUT D. 2000. Induction of protective immunity against toxoplasmosis in mice by DNA immunization with a plasmid encoding Toxoplasma gondii GRA4 gene. Vaccine 18: 2512-2521.
16. DOOLAN DL AND HUFFMAN SL. 2001, DNA-based vaccines against malaria: status and promise of the Multi-Stage Malaria DNA Vaccine Operation. Int J Parasitol 31: 753-762.
17. DOOLAN DL, HUFFMAN SL, SOUTHWOOD S, WENTWORTH PA, SIDNEY J, CHESNUT KW, KEOGH E, APPELLA E, NUTMAN TB, LAL AA, GORDON DM, OLOO A AND SETTE A. 1997. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity 7: 97-112.
18. DOS SANTOS RR, Rossi MA, LAUS JL, SILVA JS, SAVINO W AND MENGEL J. 1992. Anti-CD4 abrogates rejection and reestablishes long-term tolerance to syngeneic newborn hearts grafted in mice chronically infected with Trypanosoma cruzi. J Exp Med 175: 29-39.
19. FRALISH BH AND TARLETON RL. 2003. Genetic immunization with LYT1 or a pool of trans-sialidase genes protects mice from lethal Trypanosoma cruzi infection. Vaccine 21: 3070-3080.
20. FUJIMURA AE, KlNOSHITA SS, PEREIRA-CHIOCCOLA VL AND RODRIGUES MM. 2001. DNA sequences encoding CD4+ and CD8+ T-cell epitopes are important for efficient protective immunity induced by DNA vaccination with a Trypanosoma cruzi gene. Infect Immun 69: 5477-5486.
21. GARG N AND TARLETON RL. 2002. Genetic immunization elicits antigen-specific protective immune responses and decreases disease severity in Trypanosoma cruzi infection. Infect Immun 70: 5547-5555.
22. GAZZINELLI RT, HAKIM FT, HIENY S, SHEARER GM AND SHER A. 1991. Synergistic role of CD4+ and CD8+ T lymphocytes in IFN-gamma production and protective immunity induced by an attenuated Toxoplasma gondii vaccine. J Immunol 146: 286-292.
23. GILBERT SC, PLEBANSKI M, GUPTA S, MORRIS J, COX M, AIDOO M, KWIATKOWSKI D, GREENWOOD BM, WHITTLE HC AND HILL AV. 1998. Association of malaria parasite population structure, HLA, and immunological antagonism. Science 279: 1173-1177.
24. GONZALEZ JM, PETER K, ESPOSITO F, NEBIE I, TIERCY JM, BONELO A, AREVALO-HERRERA M, VALMORI D, ROMERO P, HERRERA S, CORRADIN G AND LOPEZ JA. 2000. HLA-A*0201 restricted CD8+ T-lymphocyte responses to malaria: identification of new Plasmodium falciparum epitopes by IFN-gamma ELISPOT. Parasite Immunol 22: 501-514.
25. GONZALEZ-ASEGUINOLAZA G, VAN KAER L, BERGMANN CC, WILSON JM, SCHMIEG J, KRONENBERG M, NAKAYAMA T, TANIGUCHI M, KOEZUKA Y AND TSUJI M. 2002. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 195: 617-624.
26. GURUNATHAN S, SACKS DL, BROWN DR, REINER SL, CHAREST H, GLAICHENHAUS N AND SEDER RA. 1997. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 186: 1137-1147.
27. GURUNATHAN S, STOBIE L, PRUSSIN C, SACKS DL, GLAICHENHAUS N, IWASAKI A, FOWELL DJ, LOCKSLEY RM, CHANG JT, WU CY AND SEDER RA. 2000. Requirements for the maintenance of Th1 immunity in vivo following DNA vaccination: a potential immunoregulatory role for CD8+ T cells. J Immunol 165: 915-924.
28. HALONEN SK AND WEISS LM. 2000. Investigation into the mechanism of gamma interferon-mediated inhibition of Toxoplasma gondii in murine astrocytes. Infect Immun 68: 3426-3430.
29. HANKE T, SAMUEL RV, BLANCHARD TJ, NEUMANN VC, ALLEN TM, BOYSON JE, SHARPE SA, COOK N, SMITH GL, WATKINS DI, CRANAGE MP AND MCMICHAEL AJ. 1999. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73: 7524-7532.
30. HIGUCHI MD, RIES MM, AIELLO VD, BENVENUTI LA, GUTIERREZ PS, BELLOTTI G AND PILEGGI F. 1997. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg 56: 485-489.
31. HILL AV, ELVIN J, WILLIS AC, AIDOO M, ALLSOPP CE, GOTCH FM, GAO XM, TAKIGUCHI M, GREENWOOD BM, TOWNSEND AR AND AL E. 1992. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360: 434-439.
32. HOFFMAN SL, GOH LM, LUKE TC, SCHNEIDER I, LE TP, DOOLAN DL, SACCI J, DE LA VEGA P, DOWLER M, PAUL C, GORDON DM, STOUTE JA, CHURCH LW, SEDEGAH M, HEPPNER DG, BALLOU WR AND RICHIE TL. 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 1155-1164.
33. HOLSCHER C, KOHLER G, MULLER U, MOSSMANN H, SCHAUE GA AND BROMBACHER F. 1998. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma crwzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 66: 1208-1215.
34. HUBER M, TIMMS E, MAK TW, ROLLINGHOFF M AND LOHOFF M. 1998. Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. Infect Immun 66: 3968-3970.
35. KENT SJ, ZHAO A, BEST SJ, CHANDLER JD, BOYLE DB AND RAMSHAW IA. 1998. Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J Virol 72: 10180-10188.
36. KHAN IA, SMITH KA AND KASPER LH. 1988. Induction of antigen-specific parasiticidal cytotoxic T cell splenocytes by a major membrane protein (P30) of Toxoplasma gondii. J Immunol 141: 3600-3605.
37. KHAN IA, SMITH KA AND KASPER LH. 1990. Induction of antigen-specific human cytotoxic T cells by Toxoplasma gondii. J Clin Invest 85: 1879-1886.
38. KHAN IA, ELY KH AND KASPER LH. 1991. A purified parasite antigen (p30) mediates CD8+ T cell immunity against fatal Toxoplasma gondii infection in mice. J Immunol 147: 3501-3506.
39. KHAN IA, ELY KH AND KASPER LH. 1994. Antigenspecific CD8+ T cell clone protects against acute Toxoplasma gondii infection in mice. J Immunol 152: 1856-1860.
40. KHAN IA, MATSUURA T AND KASPER LH. 1998. Inducible nitric oxide synthase is not required for long-term vaccine-based immunity against Toxoplasma gondii. J Immunol 161: 2994-3000.
41. KIMA PE, RUDDLE NH AND MCMAHON-PRATT D. 1997. Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous Leishmania antigen to CD8+ T cells. J Immunol 159: 1828-1834.
42. KUMAR A, KUMAR S, LE TP, SOUTHWOOD S, SIDNEY J, COHEN J, SEITE A AND HUFFMAN SL. 2001. HLA-A*01 -restricted cytotoxic T-lymphocyte epitope from the Plasmodium falciparum circumsporozoite protein. Infect Immun 69: 2766-2771.
43. KUMAR S AND TARLETON RL. 1998. The relative contribution of antibody production and CD8+ T cell function to immune control of Trypanosoma cruzi. Parasite Immunol 20: 207-216.
44. LI S, RODRIGUES M, RODRIGUEZ D, RODRIGUEZ JR, ESTEBAN M, PALESE P, NUSSENZWEIG RS AND ZAVALA F. 1993. Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci USA 90: 5214-5218.
45. LOCKSLEY RM, REINER SL, HATAM F, LITTMAN DR AND KILLEENN. 1993. Helper T cells without CD4: control of Leishmaniasis in CD4-deficient mice. Science 261: 1448-1451.
46. LOPEZ JA, WEILENMAN C, AUDRAN R, ROOGERO MA, BONELO A, TlERCY JM, SPERTINI F AND CORRADIN G. 2001. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol 31: 1989-1998.
47. LOW HP, SANTOS MA, WIZEL B AND TARLETON RL. 1998. Amastigote surface proteins of Trypanosoma cruzi are targets for CD8+ CTL. J Immunol 160: 1817-1823.
48. MALIK A, EGAN JE, HOUGHTEN RA, SADOFF JC AND HOFFMAN SL. 1991. Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein. Proc Natl Acad Sci USA 88: 3300-3304.
49. MCCONKEY SJ, REECE WH, MOORTHY VS, WEBSTER D, DUNACHIE S, BUTCHER G, VUOLA JM, BLANCHARD TJ, GOTHARD P, WATKINS K, HANNAN CM, EVERAERE S, BROWN K, KESTER KE, CUMMINGS J, WILLIAMS J, HEPPNER DG, PATHAN A, FLANAGAN K, ARULANANTHAM N, ROBERTS MT, ROY M, SMITH GL, SCHNEIDER J, PETO T, SINDEN RE, GILBERT SC AND HILL AV. 2003. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 9: 729-735.
50. MIYAHIRA Y, GARCIA-SASTRE A, RODRIGUEZ D, RODRIGUEZ JR, MURATA K, TSUJI M, PALESE P, ESTEBAN M, ZAVALA F AND NUSSENZWEIG RS. 1998. Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+ responses in mice. Proc Natl Acad Sci USA 95: 3954-3959.
51. MUNOZ-FERNANDEZ MA, FERNANDEZ MA AND FRESNO M. 1992. Synergism between tumor necrosis factoralpha and Interferon- gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol 22: 301-307.
52. MURATA K, GARCIA-SASTRE A, TSUJI M, RODRIGUES M, RODRIGUEZ D, RODRIGUEZ JR, NUSSENZWEIG RS, PALESE P, ESTEBAN M AND ZAVALA F. 1996. Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 173: 96-107.
53. NIELSEN HV, LAUEMOLLER SL, CHRISTIANSEN L, BUUS S, FOMSGAARD A AND PETERSEN E. 1999. Complete protection against lethal Toxoplasma gondii infection in mice immunized with a plasmid encoding the SAG1 gene. Infect Immun 67: 6358-6363.
54. OCKENHOUSE CF, SUN PF, LANAR DE, WELLDE BT, HALL BT, KESTER K, STOUTE JA, MAGILL A, KRZYCH U, PARLEY L, WIRTZ RA, SADOFF JC, KASLOW DC, KUMAR S, CHURCH LW, CRUTCHER JM, WIZEL B, HUFFMAN S, LALVANI A, HILL AV, TINE JA, GUITO KP, DE TAISNE C, ANDERS R, BALLOU WR AND AL E. 1998. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 177: 1664-1673.
55. OLIVEIRA-FERREIRA J, MIYAHIRA Y, LAYTON GT, SAVAGE N, ESTEBAN M, RODRIGUEZ D, RODRIGUEZ JR, NUSSENZWEIG RS AND ZAVALA F. 2000. Immunogenicity of Ty-VLP bearing a CD8(+) T cell epitope of the CS protein of P. yoelii: enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 18: 1863-1869.
56. PARKER SJ, ROBERTS CW AND ALEXANDER J. 1991. CD8+ T cells are the major lymphocyte subpopulation involved in the protective immune response to Toxoplasma gondii in mice. Clin Exp Immunol 84; 207-212.
57. PLEBANSKI M, AIDOO M, WHITTLE HC AND HILL AV. 1997. Precursor frequency analysis of cytotoxic T lymphocytes to pre-erythrocytic antigens of Plasmodium falciparum in West Africa. J Immunol 158: 2849-2855.
58. PLEBANSKI M, GILBERT SC, SCHNEIDER J, HANNAN CM, LAYTON G, BLANCHARD T, BECKER M, SMITH G, BUTCHER G, SINDEN RE AND HILL AV. 1998. Protection from Plasmodium berghei infection by priming and boosting T cells to a tingle class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 28: 4345-4355.
59. PLOEGH HL. 1998. Viral strategies of immune evasion. Science 280: 248-253.
60. POMPEU MM, BRODSKYN C, TEIXEIRA MJ, CLARENCIO J, VAN WEYENBERG J, COELHO IC, CARDOSO SA, BARRAL A AND BARRAL-NETTO M. 2001. Differences in gamma interferon production in vitro predict the pace of the in vivo response to Leishmania amazonensis in healthy volunteers. Infect Immun 69: 7453-7460.
61. ROBINSON HL, MONTEFIORI DC, JOHNSON RP, MANSON KH, KALISH ML, LIFSON JD, RIZVI TA, LU S, HU SL, MAZZARA GP, PANICALI DL, HERNDON JG, GLICKMAN R, CANDIDO MA, LYDY SL, WYAND MS AND MCCLURE HM. 1999. Neutralizing antibodyindependent Containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 5: 526-534.
62. RODRIGUES EG, ZAVALA F, EICHINGER D, WILSON JM AND TSUJI M. 1997. Single immunizing dose of recombinant adenovirus efficiently induces CD8+ T cell-mediated protective immunity against malaria. J Immunol 158: 1268-1274.
63. RODRIGUES EG, CLAASSEN J, LEE S, WILSON JM, NUSSENZWEIG RS AND TSUJI M. 2000a. Interferongamma-independent CD8+ T cell-mediated protective anti-malaria immunity elicited by recombinant adenovirus. Parasite Immunol 22: 157-160.
64. RODRIGUES M, NUSSENZWEIG RS, ROMERO P AND ZAVALA F. 1992. The in vivo cytotoxic activity of CD8+ T cell clones correlates with their levels of expression of adhesion molecules. J Exp Med 175: 895-905.
65. RODRIGUES M, LI S, MURATA K, RODRIGUEZ D, RODRIGUEZ JR, BACIK I, BENNINK JR, YEWDELL JW, GARCIA-SASTRE A, NUSSENZWEIG RS, ESTEBAN M, PALESE P AND ZAVALA F. 1994. Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity. J Immunol 153: 4636-4648.
66. RODRIGUES MM, CORDEY AS, ARREAZA G, CORRADIN G, ROMERO P, MARYANSKI JL, NUSSENZWEIG RS AND ZAVALA F. 1991. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol 3: 579-585.
67. RODRIGUES MM, RIBEIRAO M, PEREIRA-CHIOCCOLA V, RENIA L AND COSTA F. 1999. Predominance of CD4 Th1 and CD8 Tc1 cells revealed by characterization of the cellular immune response generated by immunization with a DNA vaccine containing a Trypanosoma cruzi gene. Infect Immun 67: 3855-3863.
68. RODRIGUES MM, RlBEIRAO M AND BOSCARDIN SB. 2000b. CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism. Immunol Lett 73: 43-50.
69. ROMERO P, MARYANSKI JL, CORRADIN G, NUSSENZWEIG RS, NUSSENZWEIG V AND ZAVALA F. 1989. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature 341: 323-326.
70. ROTTENBERG ME, BAKHIET M, OLSSON T, KRISTENSSON K, MAK T, WIGZELL H AND ORN A. 1993. Differential susceptibilities of mice genomically deleted of CD4 and CD8 to infections with Trypanosoma cruzi or Trypanosoma brucei. Infect Immun 61: 5129-5133.
71. SCHNEIDER J, GILBERT SC, BLANCHARD TJ, HANKE T, ROBSON KJ, HANNAN CM, BECKER M, SINDEN R, SMITH GL AND HILL AV. 1998. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Mod 4: 397-402.
72. SCHOFIELD L, VlLLAQUIRAN J, FERREIRA A, SCHEL LEKENS H, NUSSENZWEIG R AND NUSSENZWEIG V. 1987. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330: 664-666.
73. SEDEGAH M, JONES TR, KAUR M, HEDSTROM R, HOBART P, TINE JA AND HUFFMAN SL. 1998. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 95: 7648-7653.
74. SEDEGAH M, WEISS W, SACCI JBJ, CHAROENVIT Y, HEDSTROM R, GOWDA K, MAJAM VF, TlNE J, KUMAR S AND HOBART P HS. 2000. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant pox virus. J Immunol 164: 5905-5912.
75. SEPULVEDA P, HONTEBEYRIE M, LIEGEARD P, MASCILLI A AND NORRIS KA. 2000. DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection. Infect Immun 68: 4986-4991.
76. SOARES IS AND RODRIGUES MM. 1998. Malaria vaccine: roadblocks and possible solutions. Braz J Med Biol Res 31: 317-332.
77. SOARES MB, PONTES-DE-CARVALHO L AND RIBEIRO-DOS-SANTOS R. 2001a. The pathogenesis of Chagas' disease: when autoimmune and parasite-specific immune responses meet. An Acad Bras Cienc 73: 547-559.
78. SOARES MB, SILVA-MOTA KN, LIMA RS, BELLINTANI MC, PONTES-DE-CARVALHO L AND RIBEIRO-DOS-SANTOS R. 2001b. Modulation of chagasic cardiomyopathy by interleukin-4: dissociation between inflammation and tissue parasitism. Am J Pathol 159: 703-709.
79. STENGER S, ROSAT JP, BLOOM BR, KRENSKY AM AND MODLIN RL. 1999. Granulysin: a lethal weapon of cytolytic T cells. Immunol Today 20: 390-394.
80. SUZUKI Y, ORELLANA MA, SCHREIBER RD AND REMINGTON JS. 1988. Interferon-gamma: the major mediator of resistance against Toxoplasma gondii. Science 240: 516-518.
81. TARLETON RL, KOLLER BH, LATOUR A AND POSTAN M. 1992. Susceptibility of beta 2-microglobulin-deficient mice to Trypanosoma cruzi infection. Nature 356: 338-340.
82. TARLETON RL, GRUSBY MJ AND ZHANG L. 2000. Increased susceptibility of Stat4-deficient and enhanced resistance in Stat6-deficient mice to infection with Trypanosoma cruzi. J Immunol 165: 1520-1525.
83. TSUJI M, MIYAHIRA Y, NUSSENZWEIG RS, AGUET M, REICHEL M AND ZAVALA F. 1995. Development of antimalaria immunity in mice lacking IFN-gamma receptor. J Immunol 154: 5338-5344.
84. TSUJI M, BERGMANN CC, TAKITA-SONODA Y, MURATA K, RODRIGUES EG, NUSSENZWEIG RS AND ZAVALA F. 1998. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 72: 6907-6910.
85. UDHAYAKUMAR V, ONGECHA JM, SHI YP, AIDOO M, ORAGO AS, OLOO AJ, HAWLEY WA, NAHLEN BL, HUFFMAN SL, WEISS WR AND LAL AA. 1997. Cytotoxic T cell reactivity and HLA-B35 binding of the variant Plasmodium falciparum circumsporozoite protein CD8+ CTL epitope in naturally exposed Kenyan adults. Eur J Immunol 27: 1952-1957.
86. VERCAMMEN M, SCORZA T, HUYGEN K, DE BRAEKELEER J, DIET R, JACOBS D, SAMAN E AND VERSCHUEREN H. 2000. DNA vaccination with genes encoding Taxoplasma gondii antigens GRA1, GRA7, and ROP2 induces partially protective immunity against lethal challenge in mice. Infect Immun 68: 38-45.
87. WANG R, DOOLAN DL, LE TP, HEDSTROM RC, COONAN KM, CHAROENVIT Y, JONES TR, HOBART P, MARGALITH M, NG J, WEISS WR, SEDEGAH M, DE TAISNE C, NORMAN JA AND HUFFMAN SL. 1998. Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine. Science 282: 476-480.
88. WANG R, EPSTEIN J, BARACEROS FM, GORAK EJ, CHAROENVIT Y, CARUCCI DJ, HEDSTROM RC, RAHARDJO N, GAY T, HOBART P, STOUT R, JONES TR, RICHIE TL, PARKER SE, DOOLAN DL, NORMAN J AND HUFFMAN SL. 2001. Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine. Proc Natl Acad Sci USA 98: 10817-10822.
89. WEISS WR, SEDEGAH M, BEAUDOIN RL, MILLER LHAND GOOD ME 1988. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 85: 573-576.
90. WIZEL B, HOUGHTEN RA, PARKER KC, COLIGAN JE, CHURCH P, GORDON DM, BALLOU WR AND HUFFMAN SL. 1995a. Irradiated sporozoite vaccine induces HLA-B8-restricted cytotoxic T lymphocyte responses against two overlapping epitopes of the Plasmodium falciparum sporozoite surface protein 2. J Exp Med 182: 1435-1445.
91. WIZEL B, HOUGHTEN R, CHURCH P, TINE JA, LANAR DE, GORDON DM, BALLOU WR, SETTE A AND HOFFMAN SL. 1995b. HLA-A2-restricted cytotoxic T lymphocyte responses to multiple Plasmodium falciparum sporozoite surface protein 2 epitopes in sporozoite-immunized volunteers. J Immunol 155: 766-775.
92. WIZEL B, NUNES M AND TARLETON RL. 1997. Identification of Trypanosoma cruzi trans-sialidase family members as targets of protective CD8+ TC1 responses. J Immunol 159: 6120-6130.
93. WIZEL B, GARG N AND TARLETON RL. 1998a. Vaccination with trypomastigote surface antigen 1-encoding plasmid DNA confers protection against lethal Trypanosoma cruzi infection. Infect Immun 66: 50735081.
94. WIZEL B, PALMIERI M, MENDOZA C, ARANA B, SIDNEY J, SETTE A AND TARLETON R. 1998b. Human infection with Trypanosoma cruzi induces parasite antigen-specific cytotoxic T lymphocyte responses. J Clin Invest 102: 1062-1071.
95. YANO A, AOSAI F, YANG TH, HE N, MUN HS, LIU H, INOKO H AND NOROSE K. 1997. Correlation between direct binding ability of synthetic T. gondii SAGI peptides to HLA-A2 measured by a sensor for surface plasmon resonance and antigenicity of the peptides for T. gondii-infscted cell-specific CTL. Biochem Biophys Res Commun 236: 257-261.
96. YAP GS AND SHER A. 1999. Effector cells of both non-hemopoietic and hemopoietic origin are required for interferon (IFN)-gamma- and tumor necrosis factor (TNF)-alpha-dependent host resistance to the intracellular pathogen, Toxoplasma gondii. J Exp Med 189: 1083-1092.
97. ZAVALA F, RODRIGUES M, RODRIGUEZ D, RODRIGUEZ JR, NUSSENZWEIG RS AND ESTEBAN M. 2001. A striking property of recombinant poxviruses: efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 280: 155-159.